Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone for severe pediatric community-acquired pneumonia
NCT05768204Phase 4Recruiting
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of prednisolone in community acquired pneumonia (CAP) (2 arms). Primary endpoint: Rate of early treatment success at Day 3. Started Mar 2023; status: recruiting.
02
Drugs
prednisolone
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT05768204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768204.